9 results about "Histone Acetyltransferases" patented technology

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

Provided are a compound defined by chemical formula 1, a stereoisomer thereof, a tautomer thereof, and a pharmaceutically acceptable salt thereof. In chemical formula 1, R is a site which binds to a histone acetyl transferase region of EP300. The compound of the present invention can reduce the intracellular level of EP300. [Chemical formula 1]

Cell culture media comprising luteinizing hormone, follicle-stimulating hormone and at least one histone acetyltransferase inhibitor or reverse transcriptase inhibitor are provided. Methods of in vitro maturing a human oocyte, determining suitability for in vitro maturation, as well as kits comprising media, luteinizing hormone, follicle-stimulating hormone and at least one histone acetyltransferase inhibitor or reverse transcriptase inhibitor are also provided.

Addressing the challenges of low genome editing efficiency and low efficiency in producing plants with mutations introduced into target genes, this research aims to provide plant genome editing technology with higher genome editing efficiency. [Solution] A method for producing genome-edited plants, comprising introducing a histone acetyltransferase expression cassette and a site-specific nuclease expression cassette into a plant.

Methods to identify modulators of histone acetyltransferases are described. Modulators of histone acetyltransferases can be used to treat individuals. In some instances, modulators of histone acetyltransferases are utilized to treat individuals having a neoplasm.

The invention provides application of histone acetyltransferase GhGCN5 in regulation and control of cotton fiber development, and relates to the technical field of molecular breeding. After the GhGCN5 gene is edited in cotton, both the initial number of fibers and the length of mature fibers are increased; the overexpression GhGCN5 gene can significantly inhibit the growth of cotton fibers in the initial and elongation stages, and leads to the reduction of the length and quantity of mature fibers. The GhGCN5 gene capable of regulating and controlling the development of the cotton fibers, provided by the invention, provides new gene resources and theoretical support for the quality improvement of the cotton fibers.

Disclosed herein are heterobifunctional compounds comprising a BCL6 binding moiety and a moiety that binds to a bromodomain of a histone acetyltransferase (HAT) wherein the two moieties are linked by a linker. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, for example, to treat proliferative diseases, such as cancer.

The disclosure, in one aspect, relates to methods for treating cancer in a subject, the methods including at least the steps of administering at least one drug from each of at least two classes selected from an inhibitor of poly-ADP ribose polymerase (PARP inhibitor), an inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs inhibitor), an inhibitor of wild-type isocitrate dehydrogenase (IDH inhibitor), an inhibitor of histone acetyltransferase (HAT inhibitor), an inhibitor of histone deacetylase (HDAC inhibitor), an inhibitor of DNA polymerase Θ (POLΘ inhibitor), an inhibitor of platelet-derived growth factor receptor (PDGFR inhibitor), and a DNA alkylating agent to the subject. In any of these aspects, the disclosed method allows for administering lower doses of the drugs in combination compared to administration as single drugs while preventing the recurrence of the cancer, preventing drug resistance of the cancer, and reducing side effects associated with cancer treatment.